# Editas Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/editas-medicine

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.editasmedicine.com/
- Total disclosed funding: $141M
- Latest round: Series B (Aug 4, 2015)
- Investors on record: 16

## About

Editas Medicine, Inc. is a biotechnology company focused on developing genomic medicines through CRISPR gene editing technology to address serious genetic disorders.Founded in 2013 and headquartered in Cambridge, US, Editas Medicine specializes in genomic medicine and gene editing. The firm has undergone three funding rounds with its latest being an IPO in February 2016, raising USD 94.4 mn. The founder, George Church, is a notable figure in genetics, and the current CEO is Gilmore ONeill.Editas Medicine is dedicated to developing genomic medicines utilizing CRISPR gene editing technology. Their primary focus is on experimental therapies for severe genetic diseases, targeting conditions like sickle cell disease and beta thalassemia. The company uses targeted lipid nanoparticle delivery systems for precise gene editing, aiming to improve treatment efficacy and safety for patients worldwide, particularly in North America, Europe, and parts of Asia.In the most recent fiscal year 2024, Editas Medicine reported revenue of USD 32.31 mn and an EBITDA of USD -245.34 mn. The company's revenue model centers on commercializing its proprietary gene therapies, often in collaboration with partners in the biotechnology and pharmaceutical sectors, generating revenue through licensing agreements and joint ventures as products advance through clinical trials.Editas Medicine plans to leverage its recent funding from the IPO in February 2016, which raised USD 94.4 mn, to support the development of new genomic therapies targeting serious genetic diseases. The company aims to expand its market reach specifically into regions with high unmet medical needs, including additional markets in Europe and Asia by 2025. This strategic growth will focus on advancing their product pipeline towards clinical trials and eventual market introduction.

## Funding rounds

- Series B, Aug 4, 2015, $120M — Flagship Pioneering, T Rowe Price, Polaris Partners, Alexandria Venture Investments, Khosla Ventures, Viking Global Investors, Third Rock Ventures, Fidelity Investments, GV, Omega Funds, Mass General Brigham Ventures, Jennison Associates, Casdin Capital, Deerfield Management, EcoR1 Capital, Cowen Investment Management
- Series A, Nov 20, 2013, $21M — Flagship Pioneering, Polaris Partners, Third Rock Ventures, Mass General Brigham Ventures

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- Jennison Associates — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Cowen Investment Management — Series B